MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas
P16 expression was variable and did not correlate with either MTAP expression or <i>CDKN2A</i> FISH results. MTAP IHC is a promising surrogate marker for the evaluation of <i>CDKN2A</i> status in meningiomas.
Authors
- Gökçe Törüner (ORCID: https://orcid.org/0000-0002-5305-6337)
- Oluwaseun Ogunbona (ORCID: https://orcid.org/0000-0001-5116-7204)
- Hanim I. Ozkizilkaya
- Phyu P. Aung (ORCID: https://orcid.org/0000-0002-3398-0573)
- Anjali Vinocha
- Leomar Y. Ballester (ORCID: https://orcid.org/0000-0002-6854-6830)
- Antonio Dono (ORCID: https://orcid.org/0000-0002-8041-8399)
- Carlos Kamiya Matsuoka (ORCID: https://orcid.org/0000-0003-3216-2728)
- Franco DeMonte (ORCID: https://orcid.org/0000-0002-6488-3645)
- Yoshua Esquenazi (ORCID: https://orcid.org/0000-0002-9757-1453)
Institutions
- Memorial Hermann (US)
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3390/cancers16193299
- Citations
- 10
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.38